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negative in serum testing. Sonography and CT scanning showed no dis-
tinguishable tumor lesions.
Laparoscopic surgery was performed under general anesthesia.
There was approximately 10,000 ml ascitic ﬂuid within the abdominal
cavity. Multiple intestine adhesions were observed. One tumor lesion
was found on the surface of the uterorectal fossa peritoneum. The diam-
eter of this tumor was 2 cm. There were also some other small lesions
scattering on the surface of the peritoneum as shown in Fig. 1. These
tumor lesionswere all removed. The intra-operative frozen section re-Introduction
Aggressive Angiomyxoma (AAM) is a rare soft tissue neoplasm
which predominantly occurs at the female pelvic peritoneum and
perineum region, with female-to-male ratio is 6.6:1(Chan et al.,
2000). AAM is characterized as non-encapsulated and slow-growing
benign tumor. However, their locally invasive and recurrent nature
often leads to difﬁculties in clinical treatment. On the other side,
misdiagnosis is also a problem because of their no-special clinical
representations. So far, 310 papers were retrieved in Pubmed using
search key word “Aggressive Angiomyxoma”. However, most of these
papers are case report because of their rarity, which is also responsible
for the deﬁciency of diagnosis and treatment experience of this disease.
In this paper, we present a case of small-sized AAM complicating with
massive ascites which has not been reported before. We hope that the
clinical procedure of this case would offer more useful informations
on this disease.Case report
A 30 years-old womanwas transferred to our unit from department
of gastroenterology for unexplainable massive ascites. The patient's ab-
domen circumference and body weight have been increasing gradually
in the past 2 years. She has been admitted to department of gastroen-
terology in our hospital followed by detailed systemic examination in-
cluding CT scanning. However, the source of ascites was not found. So
laparoscopic exploration surgery was recommended. The patient hadAscitess.
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-ND license.sult was necrotic adipose tissue. Postoperation pathology showed
diamond-shaped or stellate tumor cells in loose interstitial tissues.
The ﬁnal pathological diagnosis was Aggressive Angiomyxoma as
shown in Fig. 2. Immunohistochemical staining results showed:
CD34(+), SMA(+), Desmin(+), Vimentin(+), mesothelial cell(+),
ER(+), and PR(+). Positive CD34 signals were shown in Fig. 3.
The patient received further GnRH-a(Goserelin) treatment (3.6 mg
i.h. per 28 days, 6 cycles totally) after surgery. GnRH-a was effective in
controlling the ascites. However, GnRH-a was replaced by oral contra-
ceptive drug(Marvelon) because of its heavy medical cost 6 months
later. The ascitic ﬂuid appeared again. Eventually, the patient received
another surgery to remove all pelvic ﬂoor perineum tissues. The treat-
ment was successful with no ascites appeared after the second opera-
tion. No additional therapy was used (GnRHa) since then and she was
followed up with no evidence of recurrence.
Discussion
Aggressive Angiomyxoma (AAM) was ﬁrst described by Steeper
and Rosai at the 72th Meeting of Internal Academy of Pathology in
1983(Steeper and Rosai, 1983). AAM mainly occurs in the female
vulvar and abdominal cavity. This disease has the nature of “being
aggressive” which means that it has its locally inﬁltrative and recur-
rent characters. Patients are often asymptomatic or presents as valva
tumors. Compression to urinary system or intestinal system occurs
only when the tumor is large enough. The size of AAM varies greatly
ranging from 1 cm to 60 cm based on reports. It is hard to diagnose
AAM without pathologic evidence. Misdiagnosis rate is as high as
82% before surgery (Gungor et al., 2004). Imaging examinations in-
cluding CT, MRI and pelvic DSA are essential for evaluating the extent of
lesions. Signals of immunohistochemical examination are useful for diag-
nosis in some cases. However, its value is also limited because of the over-
lap with other diseases such as angiomyoﬁbroblastoma and cellular
angioﬁbroma. Almost all AAM show positive Vimentin and Desmin sig-
nals and negative S-100 signals. The positive rates of CD34, SMA, a-SMA,
Fig. 1. Tumor lesions located on the surface of peritoneum. Fig. 3. Positive CD34 signals in the vascular endothelium cells.
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case, immunohistochemical staining test results showed CD34(+), SMA
(+), Desmin(+), Vimentin(+), mesothelial cell(+), ER(+) and PR(+).
AAM often occurs in the reproductive ages. Some reports revealed
that the lesion growed during pregnancy, suggesting that hormones
may play roles in its development and progression (Han-Geurts
et al., 2006; Fishman et al., 1995). Fetsch et al (Fetsch et al., 1996)
reported that the positive rates for ER and PR in AAM tissues were
93% and 90%, respectively. Havel et al reported positive ER and nega-
tive PR, while Htwe reported one case whose tumor growed rapidly
during pregnancy with strong positive PR and negative ER (Havel
et al., 1994; Htwe et al., 1995). So AAM is believed to be hormone-
dependent tumor, which is the theory basis of hormone treatment.
The standard treatment procedure for AAM has not been estab-
lished yet. In order to remove the lesions completely, wide local resec-
tion is the traditional choice. However, the recurrence rate is rather
high because the tumor often inﬁltrates into surrounding fat and mus-
cle tissues. For the tumors with positive ER and/or PR which could not
be resected completely, hormone treatment is reasonable. Successful
cases have been reported using GnRH agonist treatment against pri-
mary or recurrent tumors (McCluggage et al., 2006; Shinohara et al.,
2004). In most of these cases GnRH agonist was used as postoperative
adjuvant treatment. However, some authors reported the primary
treatment of AAM with GnRH agonist without surgery or prior to sur-
gery. Though the drug dose was almost the same, there was no con-
sensus on the treatment cycles. Most of the cases received 6 cycles
treatment. In our case GnRHa was also proved to be effective. For
the possibility of recurrence, long-term follow-up is recommended.Fig. 2. Hematoxylin and Eosin staining of the tumor tissues.This case was different from others. The patient presented unex-
plainable massive ascites without obvious lesions. Examinations of as-
citic ﬂuid and CT scanning found no evidence of tumor. Eventually,
exploration surgery seems to be the last choice. During operation only
a small tumorwas found locating at the uterorectal fossa. Theﬁnal diag-
nosis was AAM. And so, when a woman presents unexplainable ascites,
the possibility of AAM should be considered despite of its rarity. Postop-
erative GnRH agonist treatment was successful in this case. However, it
was very strange that is why such a small lesion could induce massive
ascites. In this case, all other potential causes of ascites such as liver dis-
eases, tuberculosis as well as malignant tumor were excluded. Anyway,
the etiology of the ascites in this case of angiomyxoma was unknown.
Conclusion
In this case an AAM patient who presented unexplainable massive
ascites was reported. The disease was treated successfully by surgery
and postoperative GnRH agonist administration. Due to the rarity of
this disease, more informations are still needed.
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